Lerdelimumab
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1154585521 under CC BY-SA 4.0; modifications have been made.